Table 4. Sensitivity analyses.
Hazard ratios for incidence of non-COVID-19 death among Qataris with and without matching on a SARS-CoV-2-negative test among controls in the (A) two-dose analysis and (B) three-dose analysis.
| (A) Two-dose analysis | Two-dose cohort | Unvaccinated cohort |
|---|---|---|
| Sensitivity analysis I-Restricting analysis to Qataris * | ||
| Unadjusted hazard ratiofor non-COVID-19 death (95% CI) | 0.29 (0.19–0.43) | |
| Adjusted hazard ratiofor non-COVID-19 death (95% CI)† | 0.29 (0.19–0.43) | |
| Sensitivity analysis II-Restricting analysis to Qataris and not matching by a SARS-CoV-2-negative test among controls ‡ | ||
| Unadjusted hazard ratiofor non-COVID-19 death (95% CI) | 0.40 (0.31–0.51) | |
| Adjusted hazard ratiofor non-COVID-19 death (95% CI)§ | 0.38 (0.30–0.50) | |
| (B) Three-dose analysis | Three-dose cohort | Two-dose cohort |
| Sensitivity analysis I-Restricting analysis to Qataris ¶ | ||
| Unadjusted hazard ratiofor non-COVID-19 death (95% CI) | 0.77 (0.44–1.33) | |
| Adjusted hazard ratiofor non-COVID-19 death (95% CI)** | 0.76 (0.43–1.32) | |
| Sensitivity analysis II-Restricting analysis to Qataris and not matching by a SARS-CoV-2-negative test among controls †† | ||
| Unadjusted hazard ratiofor non-COVID-19 death (95% CI) | 0.77 (0.52–1.12) | |
| Adjusted hazard ratiofor non-COVID-19 death (95% CI)** | 0.77 (0.53–1.13) | |
CI, confidence interval; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Cohorts were matched exactly one-to-one by sex, 10-year age group, type of coexisting conditions, and prior infection status. Persons who received their second vaccine dose in a specific calendar week in the two-dose cohort were additionally matched to persons who had a record for a SARS-CoV-2-negative test in that same calendar week in the unvaccinated cohort, to ensure that matched pairs had presence in Qatar over the same time period.
Adjusted for sex, 10-year age group, number of coexisting conditions, prior infection status, and calendar week of the second vaccine dose for the two-dose cohort or SARS-CoV-2-negative test for the unvaccinated cohort.
Cohorts were matched exactly one-to-one by sex, 10-year age group, type of coexisting conditions, and prior infection status.
Adjusted for sex, 10-year age group, number of coexisting conditions, and prior infection status.
Cohorts were matched exactly one-to-one by sex, 10-year age group, type of coexisting conditions, prior infection status, and calendar week of the second vaccine dose. Persons who received their third vaccine dose in a specific calendar week in the three-dose cohort were additionally matched to persons who had a record for a SARS-CoV-2-negative test in that same calendar week in the two-dose cohort, to ensure that matched pairs had presence in Qatar over the same time period.
Adjusted for sex, 10-year age group, number of coexisting conditions, prior infection status, and calendar week of the second vaccine dose.
Cohorts were matched exactly one-to-one by sex, 10-year age group, type of coexisting conditions, prior infection status, and calendar week of the second vaccine dose.